Eidos Therapeutics clinical trials
Acquired by BridgeBio, Apr 2016 · source ↗
The registry lists 11 studies whose lead sponsor is Eidos Therapeutics. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 14, 2026.
Before and after it joined BridgeBio
- First submitted before Eidos Therapeutics became part of BridgeBio
- 0
- First submitted after Eidos Therapeutics became part of BridgeBio
- 11
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Eidos Therapeutics, a BridgeBio company11 studies
Something wrong with this grouping? Tell us on the BridgeBio page.
Studies
Recruiting first, then most recently updated. Showing 11 of 11. All BridgeBio studies →
- To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)Not yet recruitingNCT07116473Phase 3
Sponsor listed in the registry: Eidos Therapeutics, a BridgeBio company · First submitted after Eidos Therapeutics became part of BridgeBio
- Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantRecruitingNCT06563895Phase 3
Sponsor listed in the registry: Eidos Therapeutics, a BridgeBio company · First submitted after Eidos Therapeutics became part of BridgeBio
- Cardiac Magnetic Resonance and Echocardiography Study With AcoramidisRecruitingNCT07695701Phase 4
Sponsor listed in the registry: Eidos Therapeutics, a BridgeBio company · First submitted after Eidos Therapeutics became part of BridgeBio
- Open-Label Study of AG10 in Patients With CardiomyopathyTerminatedNCT03536767Phase 2
Sponsor listed in the registry: Eidos Therapeutics, a BridgeBio company · First submitted after Eidos Therapeutics became part of BridgeBio
- Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR ParticipantsActive, not recruitingNCT04988386Phase 3
Sponsor listed in the registry: Eidos Therapeutics, a BridgeBio company · First submitted after Eidos Therapeutics became part of BridgeBio
- Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)WithdrawnNCT04882735Phase 3
Sponsor listed in the registry: Eidos Therapeutics, a BridgeBio company · First submitted after Eidos Therapeutics became part of BridgeBio
- Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid PolyneurophathyWithdrawnNCT04418024Phase 3
Sponsor listed in the registry: Eidos Therapeutics, a BridgeBio company · First submitted after Eidos Therapeutics became part of BridgeBio
- A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy SubjectsCompletedNCT04769479Phase 1
Sponsor listed in the registry: Eidos Therapeutics, a BridgeBio company · First submitted after Eidos Therapeutics became part of BridgeBio
- Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10CompletedNCT03294707Phase 1
Sponsor listed in the registry: Eidos Therapeutics, a BridgeBio company · First submitted after Eidos Therapeutics became part of BridgeBio
- Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid CardiomyopathyCompletedNCT03860935Phase 3
Sponsor listed in the registry: Eidos Therapeutics, a BridgeBio company · First submitted after Eidos Therapeutics became part of BridgeBio
- Study of AG10 in Amyloid CardiomyopathyCompletedNCT03458130Phase 2
Sponsor listed in the registry: Eidos Therapeutics, a BridgeBio company · First submitted after Eidos Therapeutics became part of BridgeBio